GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (LTS:0A4W) » Definitions » Short-Term Debt

ACADIA Pharmaceuticals (LTS:0A4W) Short-Term Debt : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ACADIA Pharmaceuticals Short-Term Debt?

ACADIA Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.0 Mil.


ACADIA Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for ACADIA Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Short-Term Debt Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ACADIA Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ACADIA Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


ACADIA Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Headlines

No Headlines